baltimore conference logo
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD

EP. 1: Tanios Bekaii-Saab, MD: Mutations in Colorectal Cancer

April 26th 2016

EP. 2: Tanios Bekaii-Saab, MD: RAS Mutations in Metastatic Colorectal Cancer

April 26th 2016

EP. 3: Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations

April 26th 2016

EP. 4: Tanios Bekaii-Saab, MD: RAS Mutations and the Sequence of Therapies

April 26th 2016

EP. 5: Tanios Bekaii-Saab, MD: Percentage of RAS Mutation Tests in Metastatic CRC

April 26th 2016

EP. 6: Tanios Bekaii-Saab, MD: Impeding RAS Mutation Testing

April 26th 2016

EP. 7: Tanios Bekaii-Saab, MD: Strategies to Increase RAS Testing

April 26th 2016

EP. 8: Tanios Bekaii-Saab, MD: Cost Issues With CT Regimens and Bevacizumab

April 26th 2016

EP. 9: Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer

April 26th 2016

EP. 10: Charles Fuchs, MD: Clinical Importance of RAS Mutations

April 26th 2016